Skip to main content
KYMR logo

KYMR · Kymera Therapeutics, Inc. · Executive Compensation

Track KYMR — free
$127.57 +0.40 (+0.31%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Market Cap
$10.89B
Shares
85.37M
Volume · Nov 13 808.83K Avg daily vol (3M) 828.66K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Nello Mainolfi $8,545,609
Brian Adams $6,071,041
Noah Goodman $3,172,068
Jared Gollob $2,914,330
Bruce Jacobs $2,903,236
Fiscal 2024
Executive Total
Nello Mainolfi $15,433,147
Bruce Jacobs $7,140,817
Jared Gollob $5,749,693
Ellen Chiniara $5,140,813
Jeremy Chadwick $3,462,173
Fiscal 2023
Executive Total
Nello Mainolfi $9,670,542
Jeremy Chadwick $5,001,049
Ellen Chiniara $4,962,993
Bruce Jacobs $4,155,156
Jared Gollob $3,474,154
Fiscal 2022
Executive Total
Nello Mainolfi $6,926,645
Bruce Jacobs $2,893,316
Jared Gollob $2,765,015
Elaine Caughey $1,684,511
Fiscal 2021
Executive Total
Nello Mainolfi $11,573,374
Bruce Jacobs $4,599,562
Jared Gollob $3,500,801
Elaine Caughey $3,129,295
Fiscal 2020
Executive Total
Richard Chesworth $4,534,243
Nello Mainolfi $3,678,001
Jared Gollob $1,452,716
Bruce Jacobs $1,262,902
Fiscal 2019
Executive Total
Jared Gollob $688,199

Executive changes

Person Change Filed
Terence Rooney, M.D. Appointed 2026-07-27
Jeremy Chadwick Resigned 2026-06-08
Brian R. Adams, J.D. Appointed 2025-09-03
Ellen Chiniara, J.D. Retired 2025-09-03
Jeffrey Albers Already on the board
Since at least 2020: re-election or new board role
2024-06-20
Joanna Horobin Resigned 2024-06-20
Felix J. Baker, Ph.D. Appointed 2024-04-01
Felix J. Baker, Ph.D. Appointed 2024-04-01
Jeremy Chadwick, Ph.D. Appointed 2023-05-22
Victor Sandor, M.D. Appointed 2022-11-03
Donald Nicholson, Ph.D. Resigned 2022-11-03
Leigh Morgan Appointed 2022-07-08

Leadership

Key facts CIK 1815442 CUSIP 501575104 13F (30d) 236 filings 211 filers Visit website Investor relations